Allergan dissapointed with PTAB’s reaction as Mylan petitions for IPR of Restasis patents

Allergan said on Thursday that it was disappointed in the PTAB’s decision to institute IPR proceedings regarding the patents that protect Restasis.

Allergan is currently reviewing the grounds for the decision to institute, and will continue to vigorously defend the patents in the IPR proceeding. The company added it would pursue all legal options to protect its products and intellectual property rights for this product.

The pharmaceutical company’s portfolio of intellectual property includes six patents listed in the Orange Book covering Restasis.

Irland-based drugmaker’s Hatch-Waxman litigations involving these patents against Mylan and other generic defendants remain pending in the United States District Court for the Eastern District of Texas.